Cordio Medical News
13 articles
Speak and be saved: Israeli app detects heart failure weeks before attack
Cordio Medical Presents Study Validating Voice Signature AI Tool that Monitors Congestive Heart Failure
Cordio Medical, the developer of the HearO® app, has presented positive results from their clinical study during the American Heart Associations Scientific Sessions. The HearO® app, which combines a smartphone-based mobile speech application and cloud-based computing, can detect changes in Speech Measures indicative of worsening heart failure. The study demonstrated the apps ability to identify patients at risk of worsening heart failure, offering a critical window for timely intervention and treatment. The app detected 76.3% of first and recurrent heart failure events before they occurred in the development group, and 71.4% in the test group.
Customers
The General Hospital of Valencia Uses Artificial Intelligence to Monitor Heart Failure by Voice
The General Hospital of Valencia and the Valencian Society of Cardiology are testing Cordio Medical’s HearO™ app, a voice biomarker AI solution for monitoring heart failure patients. The app has been introduced by AstraZeneca in Spain and has already been tested in Israel and the US. The app can predict 79.6% of decompensations in stable CHF patients up to 18 days before occurrence. The pilot program has been running since June with 30 patients from the Heart Failure Unit of the General Hospital of Valencia.
CustomersPartners
AstraZeneca, Bellvitge University Hospital begin pilot of Cordio Medical's app that monitors heart failure by voice
Cordio Medical, in partnership with Bellvitge University Hospital and AstraZeneca PLC, is launching a pilot program for its HearO app. The app uses AI to analyze patients speech patterns and predict possible complications in heart failure patients. The pilot aims to assess the feasibility of using the app to monitor patients in hospital and at-home settings over a six- to nine-month period. Previous studies have shown an 82% success rate in predicting a heart decompensation event up to 22 days before it occurs.
PartnersCustomers
HearO app uses AI to predict heart failure deterioration
Cordio Medicals HearO app is currently in clinical trials to assess its ability to predict heart failure deterioration using AI technology. The app uses voice signature technology to detect and predict hospitalization risks for congestive heart failure before symptoms appear. The app has over 80% accuracy in detecting heart decompensation events an average of 18 days in advance. The app is currently in US clinical trials and has received a Breakthrough Device Designation from the FDA. Cordio Medical plans to expand into the UK this year.
CustomersExpand
חברת "Cordio Medical" זיהתה אירועי אי ספיקת לב זמן רב לפני שהתרחשו
Cordio Medical, an Israeli start-up, has successfully conducted a trial of its HearO system among 180 patients across ten medical centres in Israel. The system was able to detect heart failure events an average of 18 days before they occurred. The trial involved patients sending a daily voice sample via their smartphone, with the system collecting a total of 460,000 samples. Cordio Medical recently completed a funding round raising $18 million. The company, which began its journey in the Ariel Insentiv incubator, currently employs 25 people in Or Yehuda and the United States.
InvestmentExpand
Cordio Medical HearO™ Voice Signature Technology Demonstrates Superior Standard of Care for Heart Failure Patients
Cordio Medicals HearO™ Community Study has successfully predicted heart failure events, providing opportunities for preventative care. The study evaluated the diagnostic performance of the Cordio HearO™ application in the outpatient setting for patients at risk of heart failure hospitalization. The preliminary analysis showed that the application demonstrated 80% sensitivity in predicting heart failure events, accurately predicting 44 out of 55 events. The HearO™ system can detect heart failure decompensation events about three weeks prior, allowing for early intervention. Cordio Medical develops and provides solutions for monitoring health conditions through speech analysis, aiming to improve patient health quality and mortality.
Customers
Cordio Medical raises $18 million to leverage speech processing to monitor heart failure CTech
Cordio Medical, an Israeli startup that develops solutions for monitoring health conditions through speech, has raised $18 million in funding. The funding round was led by Ceros Financial Services and Peregrine Ventures. Cordio Medicals product, HearO, uses a smartphone app to monitor and detect fluid accumulation related to Congestive Heart Failure (CHF) condition deterioration. The company plans to use the funding for a clinical validation study, health and academic partnerships, and sales team recruitment. Cordio Medical aims to go to market in the U.S. in early 2024 with final approval from the FDA.
InvestmentExpand
Israeli startup uses Hebrew U breakthrough to cut the cost of treating cancer - Sponsored Content The Times of Israel
Israeli startup HIL Applied Medical has developed technology that can significantly reduce the cost of proton-beam radiotherapy for cancer patients. The technology, based on a breakthrough by scientists at Hebrew University, allows for the delivery of proton radiotherapy in a smaller and more affordable treatment room. This makes the treatment accessible to millions of patients who currently cannot access it due to the high cost and large size of the equipment. HILs technology has the potential to create a $40 billion per annum market. The company plans to produce 200-250 proton therapy systems per year and has partnerships with Proton International for facilities in the US. HIL has received grants from various organizations and is currently raising an investment round on the OurCrowd platform.
InvestmentPartners
יחסוך מיליארדים: הפיתוח הישראלי שמקטין את תדירות האשפוזים החוזרים בבתיה"ח
A new Israeli development based on voice analysis of patients may reduce the frequency of hospital readmissions by 25%. The Israeli technology can identify deteriorations in the condition of heart patients long before they occur, potentially saving billions in unnecessary expenses. With the aging population, heart failure is one of the main causes of hospitalizations and readmissions. The technology aims to detect early signs of deterioration in heart patients using changes in their voice, which are not perceptible to the human ear. By identifying these changes, early diagnosis and treatment can prevent worsening conditions and unnecessary hospitalizations.
Customers
This New App Analyzes Your Voice Quality To Diagnose Congestive Heart Failure: Can It Help With Covid-19?
Israeli biotech start-up Cordio Medical has developed an app called Cordio HearO that can evaluate changes in voice quality to detect fluid buildup in the lungs, a sign of congestive heart failure (CHF). The app offers the potential for early detection and intervention, allowing healthcare providers to adjust medication dosing before serious symptoms develop. The app was evaluated in a small study involving 40 CHF patients and showed subtle differences in phonation between congested and non-congested patients. The app can be used to monitor patients with CHF in a home setting, with voice recordings used to track changes in fluid accumulation. The technology has the potential to save costs by enabling early detection and intervention in heart failure patients.
Customers
Cordio and Rambam Hospital will trial AI that detects coronavirus cases from speech samples
Cordio Medical will conduct a clinical trial on an app-based AI system that analyzes speech to diagnose and remotely monitor COVID-19 patients. The technology, built on Cordios existing HearO product, can detect changes in lung fluids and inflammation associated with COVID-19. The company aims to detect COVID-19 deterioration within 10-48 hours. HearO is already in use at 10 medical institutions. The article also mentions other companies and research institutions exploring AI-powered voice diagnostics for various health conditions.
Customers
Speech Analysis Startup Cordio Medical to Test Speech-Based Coronavirus Diagnostic Technology
Speech analytics startup Cordio Medical Ltd. plans to begin trials for a technology that remotely monitors and diagnoses coronavirus (Covid-19) patients. The trials will test the companys technologys ability to identify deterioration in the patients condition by analyzing the patients speech. Cordios system can detect fluid accumulation and forewarn of an anticipated deterioration in patients based on the analysis of their speech patterns. The trials will take place at the Rambam Health Care Campus in Haifa, Israel. Cordio is not the only company trying to diagnose coronavirus by analyzing speech.
Customers
